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ABSTRACT
Background  Genetic factors have a substantial role 
in determining development of rheumatoid arthritis 
(RA), and are likely to account for 50–60% of disease 
susceptibility. Genome-wide association studies have 
identiﬁ  ed non-human leucocyte antigen RA susceptibility 
loci which associate with RA with low-to-moderate risk.
Objectives  To investigate recently identiﬁ  ed RA 
susceptibility markers using cohorts from six European 
countries, and perform a meta-analysis including 
previously published results.
Methods  3311 DNA samples were collected from 
patients from six countries (UK, Germany, France, Greece, 
Sweden and Denmark). Genotype data or DNA samples 
for 3709 controls were collected from four countries 
(not Sweden or Denmark). Eighteen single nucleotide 
polymorphisms (SNPs) were genotyped using Sequenom 
MassArray technology. Samples with a >95% success 
rate and only those SNPs with a genotype success rate 
of >95% were included in the analysis. Scandinavian 
patient data were pooled and previously published 
Swedish control data were accessed as a comparison 
group. Meta-analysis was used to combine results from 
this study with all previously published data.
Results  After quality control, 3209 patients and 3692 
controls were included in the study. Eight markers (ie, 
rs1160542 (AFF3), rs1678542 (KIF5A), rs2476601 
(PTPN22), rs3087243 (CTLA4), rs4810485 (CD40), 
rs5029937 (6q23), rs10760130 (TRAF1/C5) and 
rs7574865 (STAT4)) were signiﬁ  cantly associated with RA 
by meta-analysis. All 18 markers were associated with 
RA when previously published studies were incorporated 
in the analysis. Data from this study increased the 
signiﬁ  cance for association with RA and nine markers.
Conclusions  In a large European RA cohort further 
evidence for the association of 18 markers with RA 
development has been obtained.
INTRODUCTION
Genetic factors have a substantial role in deter-
mining development of rheumatoid arthritis (RA), 
and are likely to account for 50–60% of disease 
susceptibility.1 In patients of European ancestry, 
the strongest genetic effects are conferred by the 
HLA-DRB1 locus on chromosome 6,2 (speciﬁ  cally 
the alleles encoding the shared epitope) and the 
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protein tyrosine phosphatase 22 (PTPN22) gene on 
chromosome 1p13.3
Recently, a number of potential RA genetic sus-
ceptibility loci, associating with RA susceptibility 
with low-to-moderate risk, have been identiﬁ  ed 
through genome-wide association studies. These 
loci including 6q23, TRAF1/C5, STAT4, IL2RB, 
KIF5A, PRKCQ, IL2/IL21, CD226, CCL21, CD40, 
CTLA4  and IL2RA, deﬁ   ned by single nucleotide 
polymorphisms (SNPs), have subsequently been 
replicated in large independent panels of patients 
and healthy controls.4–20 Although these investi-
gations substantially improve our understanding 
of the genetic component of RA susceptibility in 
patients of European ancestry, they have been lim-
ited to UK, US, Dutch and Swedish patients.
AutoCure is an EU-funded research project 
within the sixth framework programme (http://
www.autocure.org, accessed 25 March 2010). 
The project includes 26 different partners from 12 
countries—from Umeå in the north of Sweden to 
Crete in southern Greece. In AutoCure we have 
assembled a large panel of samples from patients 
with RA and controls from six countries (UK, 
Germany, France, Greece, Sweden and Denmark): 
the Genetic Repository for AutoCure (GRACE) 
collection, in which we can now investigate dis-
ease susceptibility loci. The aim of this study was 
therefore to investigate the recently identiﬁ  ed RA 
susceptibility SNPs using RA cohorts from these 
six European countries, and perform a meta-
  analysis of these data together with previously 
published results.
METHODS
Cohorts
Researchers working within partner institutes 
identiﬁ   ed DNA samples from patient and con-
trol subjects and a unique anonymised identi-
ﬁ  er was assigned to each sample. Patients were 
Caucasian of European descent and fulﬁ  lled the 
1987 American College of Rheumatology clas-
siﬁ   cation criteria for genetic studies.21 22 DNA 
samples were received at the Arthritis Research 
Campaign Epidemiology Unit (arc-EU), within the 
University of Manchester, Manchester, UK. DNA 
samples were stored at −20°C before genotyping 
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and were managed on a fully integrated laboratory informa-
tion management system. A total of 3311 patient DNA samples 
were collected from six countries (Manchester and Birmingham, 
UK, n=1199; Hannover, Germany, n=222; Paris, France, n=727; 
Crete, Greece, n=300; Umeå, Sweden, n=567; Copenhagen, 
Denmark, n=296) and healthy control DNA samples were 
collected from Germany, n=217; France, n=192; and Greece, 
n=300. Control genotype data for the UK cohort (n=3000) were 
extracted from the Wellcome Trust Case–Control Consortium 
2 (WTCCC2) EGA website. Patient demographic and serologi-
cal information was gathered where collected. Ethical approval 
was obtained from each individual centre to contribute samples 
to the GRACE collection and to be used in genetic association 
studies.
Genotyping and analysis
Eighteen SNPs were selected for genotyping using Sequenom 
MassArray technology according to the manufacturer’s instruc-
tions, using iPLEX chemistry (http://www.sequenom.com, 
accessed 25 March 2010). The SNPs were markers associated 
with RA susceptibility in cohorts tested by our group and others 
and consisted of: rs1160542 (AFF3), rs2812378 (CCL21), rs763361 
(CD226), rs4810485 (CD40), rs3087243 and rs231775 (CTLA4), 
rs6822844 (IL2/IL21), rs2104286 (IL2RA), rs743777 (IL2RB), 
rs1678542 (KIF5A), rs4750316 (PRKCQ), rs7574865 (STAT4), 
rs13207033, rs5029937 and rs6920220 (6q23), rs10760130 and 
rs2900180 (TRAF1/C5) and rs2476601 (PTPN22).
Only those samples with a >95% success rate and only those 
SNPs with a genotype success rate of >95% were included in 
the analysis. Allele frequencies were calculated in both patient 
and control groups for each SNP marker, and meta-analysis was 
used to combine results for all cohorts.
Control samples were not received from Umeå or 
Copenhagen. In order to maximise the number of samples avail-
able for meta-analysis, we investigated the possibility of com-
bining data from the two Scandinavian centres and comparing 
this with previously published Swedish control data from the 
Epidemiological Investigation of Rheumatoid Arthritis (EIRA) 
cohort.13 The χ² test statistic was used to assess (at the 5% sig-
niﬁ  cance threshold) differences in allele frequency for each SNP 
between Swedish and Danish patients’ data and only where 
SNP frequencies were not signiﬁ  cantly different was data com-
bined. EIRA control data were available for 16 of the 18 SNPs 
under investigation (not rs231775 or rs5029937).
Finally, a meta-analysis incorporating GRACE samples 
with previously published data for each SNP was performed. 
Previously published data for the SNPs under investigation were 
retrieved from the literature and scrutinised to ensure that no 
overlapping samples were included in the analyses. Fixed effects 
models (Mantel–Haenszel method) were used and studies were 
weighted according to the amount of information they contained. 
Cochran’s Q and I2 test statistics were used to estimate variation 
in effects attributable to heterogeneity, and χ² p values are pre-
sented. Where the heterogeneity was signiﬁ  cant (at the 5% sig-
niﬁ  cance threshold), random effects models (DerSimonian and 
Laird method) were used, where stated, to incorporate between-
study variation in the weighting.
Power calculation
Sample size and power were calculated based on previously 
published effect sizes and are presented at the 5% signiﬁ  cance 
level.
All analyses were performed using STATA statistical software 
(StataCorp 2005: release 9; College Station, Texas, USA).
RESULTS
Cohort characteristics and quality control
Demographic, clinical and laboratory information for each 
patient cohort are presented in table 1. After removal of samples 
that did not satisfy quality control, 3209 patient and 3692 con-
trol samples remained available for analysis (success rate, 98%). 
SNP markers satisﬁ  ed Hardy–Weinberg equilibrium in healthy 
controls (at the 5% signiﬁ  cance threshold), with the exception 
of the following minor deviation: rs6920220 (6q23) UK controls; 
p=0.02 (online supplementary table 1).
Comparison of allele frequencies in centre-matched case 
control cohorts
For the UK, German, French and Greek centres, where both 
patients and controls were collected, allelic odds ratios (ORs) 
were calculated to test for the association of SNP markers 
with RA (online supplementary table 1). None of the SNPs 
associated with RA across all cohorts. However, the SNP 
markers rs2812378 (CCL21) Hannover, rs3087243 (CTLA4) 
and rs743777 (IL2RB) Paris, rs2900180, rs10760130 (TRAF1/
C5) and rs13207033 (6q23) Manchester, rs2476601 (PTPN22) 
Manchester, Paris and Hannover, rs5029937 (6q23) Manchester 
and Crete, and rs4810485 (CD40) Crete and Hannover, signiﬁ  -
cantly associated with RA (online supplementary table 1). A 
meta-analysis of the data from these four centres showed that 
ﬁ  ve SNP markers rs6920220, rs2900180, rs10760130, rs2476601 
and rs5029937 associated with RA (online   supplementary 
table 1).
Meta-analysis of the GRACE cohort, including EIRA control data
In order to include all patient data generated in this study 
in a meta-analysis we accessed previously published con-
trol data from the EIRA study,13 as a comparison group for 
Scandinavian patients. EIRA control data comprised: imputed 
data for eight loci from 660 healthy subjects and genotype 
data from up to 900 healthy subjects for eight loci (online 
supplementary table 2). No Swedish control data were avail-
able for the SNP markers rs231775 or rs5029937.
Table 1  Demographic and laboratory characteristics of GRACE cohorts
Cohort 
characteristics Manchester Birmingham Umeå Copenhagen Paris Crete Hannover
N 1087 112 567 296 727 300 222
AAO (years±SD) 54.5±15.0 57.0±14.9 55.9±14.4 48.1±15.4 – 55.4±4.3 45.3±11.9
Female (%) 68 58 67 75 – 74 77
Anti-CCP+ (%) 37 60 68 61 – 71
RF+ (%) 38 69 72 66 – 43 78
AAO, mean age at onset of symptom with SD; anti-CCP+, percentage of patients with a positive anti-cyclic citrullinated peptide titre; 
GRACE, Genetic Repository for AutoCure; N, number of observations; RF+, number of patients with a positive rheumatoid factor titre.
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was performed. Where available, allele frequency data were 
retrieved from the literature, or were requested by per-
sonal communication from the relevant primary investiga-
tor (online supplementary table 3). All 18 SNPs signiﬁ  cantly 
associated with RA in the meta-analysis (table 3). Signiﬁ  cant 
between-study heterogeneity was observed for the SNP mark-
ers rs743777 (IL2RB), rs2476601 (PTPN22), rs2900180 and 
rs10760130 (TRAF1/C5). Sensitivity testing showed that the 
between-study heterogeneity resulted from the strong effect 
at rs743777 in the original WTCCC discovery cohort.16 No 
between-study heterogeneity was observed after removal of 
this study from the meta-analysis (p=0.08). The between-study 
heterogeneity identiﬁ  ed for rs2476601 (p=0.0003), rs2900180 
(p=1.69e-06) and rs10760130 (p=9.62e-06) resulted from broad 
differences in effect sizes between individual study cohorts. 
For rs2476601 the effect was seen in the same direction for 
all cohorts considered, apart from the cohort originating from 
Crete, Greece (ﬁ  gure 1).
DISCUSSION
Through collaboration between European partner institutes 
within the AutoCure consortium (http://www.autocure.org), 
we were able to collect a large replication cohort of DNA sam-
ples from patients with RA and healthy controls, from six coun-
tries (UK, Germany, France, Greece, Sweden and Denmark). In 
a meta-analysis of four centres where both patients and con-
trols were available we were able to replicate the association 
of ﬁ  ve SNP markers with RA susceptibility, in a pan-  European 
setting (ie, rs6920220, rs2900180, rs10760130, rs2476601 and 
rs5029937). Patients from Scandinavian cohorts were not 
included in this meta-analysis.
When allele counts for Scandinavian patients were com-
pared with previously published EIRA control data the SNP 
  markers rs1678542 (OR=0.81 (95% CI 0.70 to 0.94)), rs4810485 
(OR=0.78 (95% CI 0.66 to 0.93)), rs2476601 (OR=1.54 (95% CI 
1.24 to 1.90)) and rs7574865 (OR=1.44 (95% CI 1.23 to 1.68)) 
associated with RA (results not shown). In a meta-  analysis 
incorporating all GRACE material together with previously 
published EIRA controls we observed associations with eight 
SNP markers and RA susceptibility (table 2). When SNP asso-
ciations with RA were replicated in this meta-analysis, the 
Allele frequencies for Swedish and Danish patients were 
  combined for 15 of the 16 SNPs listed in online supplementary 
table 2. The SNP marker rs2476601 differed sufﬁ  ciently in allele 
frequency between Swedish and Danish patients (at the 5% 
  signiﬁ  cance threshold) and was therefore not combined (data 
not shown; Swedish data alone contributed to the meta-analysis 
for this SNP).
In the meta-analysis incorporating GRACE and EIRA 
control data, eight of the 18 SNPs investigated were signiﬁ  -
cantly associated with RA (at the 5% signiﬁ  cance threshold) 
by   meta-analysis (ie, rs1160542 (AFF3), rs1678542 (KIF5A), 
rs2476601 (PTPN22), rs3087243 (CTLA4), rs4810485 (CD40), 
rs5029937 (6q23), rs10760130 (TRAF1/C5) and rs7574865 
(STAT4); table 2). One marker associated with RA in the 
samples from Paris (rs743777) and Hannover (rs2812378)—
OR=1.31 (95% CI 1.00 to 1.71) and OR=1.42 (95% CI 1.07 
to 1.88), respectively (online supplementary table 1), but did 
not associate with RA by meta-analysis—OR=1.07 (95% CI 
0.91 to 1.26) and 1.04 (95% CI 0.97 to 1.13), respectively. This 
observation is likely to be explained by lack of power. We 
had <80% power to detect an effect size in keeping with that 
observed in the   original studies.14 17
Between-study heterogeneity was observed for the SNP mark-
ers rs2476601 (PTPN22; p=0.01), rs4810485 (CD40; p=0.01) and 
rs7574865 (STAT4; p=0.03). These observations were due to the 
very strong effect seen for rs2476601 in the cohorts from Paris 
and Hannover (OR=2.47 (95% CI 1.63 to 3.73)) and (OR=2.05 
(95% CI 1.40 to 3.02)), respectively, and a lack of association 
observed in the cohort from Crete (OR=1.06 (95% CI 0.56 to 
2.00)); a lack of effect seen in the UK (OR=1.02 (95% CI 0.91 
to 1.14)) and Paris (OR=1.16 (95% CI 0.86 to 1.56)) cohorts 
for rs4810485; and the strong effect seen for rs7574865 in the 
Swedish cohort (OR=1.44 (95% CI 1.23 to 1.68); online supple-
mentary table 1). The marker rs7574865 did not signiﬁ  cantly 
associate with RA in any other cohort tested (online supplemen-
tary table 1).
Meta-analysis of all available data, including previously 
published data
A further meta-analysis including data from this study and all 
previously published data for the 18 SNPs under investigation 
Table 2  Meta-analysis results for AutoCure samples—GRACE collection including EIRA control data
SNP Gene Case/control MAF case MAF control Het p χ² p OR (95% CI)
rs231775 CTLA4 2272/3317 0.37 0.38 0.071 0.647 1.02 (0.94 to 1.11)
rs743777 IL2RB 3068/4048 0.33 0.32 0.086 0.408 1.07 (0.91 to 1.26)
rs763361 CD226 3152/3992 0.49 0.47 0.782 0.396 1.03 (0.96 to 1.11)
rs1160542 AFF3 3146/4062 0.49 0.47 0.854 0.029 1.08 (1.01 to 1.16)
rs1678542 KIF5A 3144/4065 0.36 0.38 0.073 0.023 0.92 (0.86 to 0.99)
rs2104286 IL2RA 3149/4066 0.24 0.26 0.898 0.115 0.94 (0.86 to 1.01)
rs2476601 PTPN22 2794/4194 0.15 0.10 0.010 6.25e-12 1.48 (1.33 to 1.66)
rs2812378 CCL21 3146/4062 0.35 0.33 0.187 0.251 1.04 (0.97 to 1.13)
rs2900180 TRAF1/C5 3147/4223 0.36 0.35 0.095 0.057 1.07 (0.99 to 1.15)
rs3087243 CTLA4 3058/4279 0.42 0.44 0.279 0.024 0.92 (0.86 to 0.99)
rs4750316 PRKCQ 3075/4046 0.18 0.19 0.525 0.501 0.97 (0.86 to 1.06)
rs4810485 CD40 3043/4044 0.24 0.25 0.010 0.033 0.91 (0.84 to 0.99)
rs5029937 6q23 2262/3379 0.04 0.03 0.166 0.002 1.40 (1.13 to 1.74)
rs6822844 IL2/IL21 3143/3998 0.16 0.16 0.329 0.656 0.98 (0.89 to 1.07)
rs6920220 6q23 3146/4066 0.21 0.21 0.479 0.093 1.08 (0.99 to 1.17)
rs7574865 STAT4 3063/4198 0.25 0.22 0.030 0.0003 1.17 (1.07 to 1.27)
rs10760130 TRAF1/C5 3155/4254 0.45 0.43 0.348 0.035 1.08 (1.01 to 1.16)
rs13207033 6q23 2984/4042 0.26 0.26 0.153 0.348 0.96 (0.89 to 1.04)
χ² p, χ² p value; Het p, heterogeneity χ² p value; EIRA, Epidemiological Investigation of Rheumatoid Arthritis; GRACE, Genetic Repository for AutoCure; MAF, minor allele frequency; 
SNP, single-nucleotide polymorphism.
24_annrheumdis121020.indd   1550 24_annrheumdis121020.indd   1550 7/5/2010   3:32:26 PM 7/5/2010   3:32:26 PMExtended report
Ann Rheum Dis 2010;69:1548–1553. doi:10.1136/ard.2009.121020 1551
T
a
b
l
e
 
3
 
M
e
t
a
-
a
n
a
l
y
s
i
s
 
o
f
 
p
r
e
v
i
o
u
s
l
y
 
p
u
b
l
i
s
h
e
d
 
a
l
l
e
l
e
 
f
r
e
q
u
e
n
c
y
 
d
a
t
a
 
t
o
g
e
t
h
e
r
 
w
i
t
h
 
d
a
t
a
 
f
r
o
m
 
o
u
r
 
s
t
u
d
y
—
A
u
t
o
C
u
r
e
S
N
P
G
e
n
e
B
e
f
o
r
e
 
A
u
t
o
C
u
r
e
 
m
e
t
a
-
a
n
a
l
y
s
i
s
M
e
t
a
-
a
n
a
l
y
s
i
s
 
a
l
l
 
d
a
t
a
M
A
F
 
c
a
s
e
M
A
F
 
c
o
n
t
r
o
l
C
a
s
e
/
c
o
n
t
r
o
l
H
e
t
 
p
χ
²
 
p
O
R
 
(
9
5
%
 
C
I
)
M
A
F
 
c
a
s
e
M
A
F
 
c
o
n
t
r
o
l
C
a
s
e
/
c
o
n
t
r
o
l
H
e
t
 
p
χ
²
 
p
O
R
 
(
9
5
%
 
C
I
)
r
s
2
3
1
7
7
5
C
T
L
A
4
0
.
4
0
0
.
3
8
3
8
8
8
/
3
3
6
7
0
.
8
6
2
0
.
0
0
3
1
.
1
1
 
(
1
.
0
4
 
t
o
 
1
.
1
8
)
0
.
3
9
0
.
3
8
6
1
6
0
/
6
6
8
4
0
.
0
9
8
0
.
0
0
9
1
.
0
7
 
(
1
.
0
2
 
t
o
 
1
.
1
3
)
r
s
7
4
3
7
7
7
I
L
2
R
B
0
.
3
3
0
.
3
1
7
9
7
0
/
7
2
7
7
0
.
0
3
9
1
.
7
7
e
-
0
7
1
.
3
3
 
(
1
.
1
9
 
t
o
 
1
.
4
8
)
0
.
3
3
0
.
3
1
1
1
0
3
8
/
1
0
6
6
5
0
.
0
0
3
1
.
4
4
e
-
0
6
1
.
2
5
 
(
1
.
1
4
 
t
o
 
1
.
3
7
)
r
s
7
6
3
3
6
1
C
D
2
2
6
0
.
4
8
0
.
4
6
7
1
0
2
/
7
0
9
3
0
.
8
3
6
0
.
0
1
1
.
0
6
 
(
1
.
0
2
 
t
o
 
1
.
1
2
)
0
.
4
8
0
.
4
7
1
0
2
5
4
/
1
0
4
2
7
0
.
9
4
9
0
.
0
0
9
1
.
0
6
 
(
1
.
0
1
 
t
o
 
1
.
1
0
)
r
s
1
1
6
0
5
4
2
A
F
F
3
0
.
4
8
0
.
4
5
7
7
5
6
/
7
7
5
5
0
.
4
7
6
.
7
3
e
-
0
7
1
.
1
2
 
(
1
.
0
7
 
t
o
 
1
.
1
8
)
0
.
4
8
0
.
4
6
1
0
9
0
2
/
1
1
1
5
8
0
.
8
1
0
1
.
1
5
e
-
0
7
1
.
1
1
 
(
1
.
0
7
 
t
o
 
1
.
1
6
)
r
s
1
6
7
8
5
4
2
K
I
F
5
A
0
.
3
5
0
.
3
7
1
1
2
3
4
/
1
4
0
8
3
0
.
5
7
6
1
.
7
0
e
-
0
8
0
.
9
0
 
(
0
.
8
7
 
t
o
 
0
.
9
3
)
0
.
3
5
0
.
3
7
1
4
3
7
8
/
1
7
4
9
0
0
.
3
5
7
3
.
6
4
e
-
0
9
0
.
9
0
 
(
0
.
8
7
 
t
o
 
0
.
9
4
)
r
s
2
1
0
4
2
8
6
I
L
2
R
A
0
.
2
6
0
.
2
8
6
9
6
3
/
7
0
4
3
0
.
0
3
4
3
.
7
4
e
-
0
5
0
.
8
9
 
(
0
.
8
5
 
t
o
 
0
.
9
4
)
0
.
2
5
0
.
2
7
1
0
1
1
2
/
1
0
4
5
0
0
.
1
9
0
2
.
4
8
e
-
0
5
0
.
9
1
 
(
0
.
8
6
 
t
o
 
0
.
9
5
)
r
s
2
4
7
6
6
0
1
P
T
P
N
2
2
0
.
1
5
0
.
1
0
1
7
2
8
5
/
1
7
3
5
3
0
.
0
0
4
7
.
3
0
e
-
9
2
1
.
6
1
 
(
1
.
5
4
 
t
o
 
1
.
6
9
)
0
.
1
5
0
.
1
0
2
0
0
7
9
/
2
0
6
7
3
0
.
0
0
0
3
2
.
3
0
e
-
9
8
1
.
6
0
 
(
1
.
5
3
 
t
o
 
1
.
6
7
)
r
s
2
8
1
2
3
7
8
C
C
L
2
1
0
.
3
6
0
.
3
4
1
1
0
0
0
/
1
3
5
7
0
0
.
6
5
8
3
.
8
5
e
-
0
7
1
.
1
0
 
(
1
.
0
6
 
t
o
 
1
.
1
5
)
0
.
3
6
0
.
3
4
1
4
1
4
6
/
1
6
9
7
5
0
.
3
5
7
7
.
7
9
e
-
0
7
1
.
0
9
 
(
1
.
0
5
 
t
o
 
1
.
1
3
)
r
s
2
9
0
0
1
8
0
T
R
A
F
1
/
C
5
0
.
3
8
0
.
3
4
9
2
1
0
/
1
0
2
8
1
2
.
0
5
e
-
0
6
1
.
0
8
e
-
1
2
1
.
1
7
 
(
1
.
1
2
 
t
o
 
1
.
2
2
)
0
.
3
8
0
.
3
4
1
2
3
5
7
/
1
3
6
2
1
1
.
6
9
e
-
0
6
6
.
5
0
e
-
1
3
1
.
1
5
 
(
1
.
1
1
 
t
o
 
1
.
1
9
)
r
s
3
0
8
7
2
4
3
C
T
L
A
4
0
.
4
2
0
.
4
5
9
3
1
4
/
9
8
6
6
0
.
3
6
2
2
.
0
6
e
-
0
7
0
.
9
0
 
(
0
.
8
6
 
t
o
 
0
.
9
3
)
0
.
4
2
0
.
4
5
1
2
3
7
2
/
1
3
2
6
7
0
.
3
2
6
4
.
0
8
e
-
0
8
0
.
9
0
 
(
0
.
8
7
 
t
o
 
0
.
9
4
)
r
s
4
7
5
0
3
1
6
P
R
K
C
Q
0
.
1
8
0
.
2
0
1
1
2
3
1
/
1
4
0
9
4
0
.
7
1
7
2
.
4
0
e
-
0
8
0
.
8
8
 
(
0
.
8
4
 
t
o
 
0
.
9
2
)
0
.
1
8
0
.
1
9
1
4
3
0
6
/
1
7
4
8
2
0
.
4
7
1
1
.
5
4
e
-
0
7
0
.
9
0
 
(
0
.
8
6
 
t
o
 
0
.
9
3
)
r
s
4
8
1
0
4
8
5
C
D
4
0
0
.
2
3
0
.
2
5
1
0
9
8
8
/
1
3
6
2
9
0
.
3
0
4
4
.
7
0
e
-
1
0
0
.
8
7
 
(
0
.
8
4
 
t
o
 
0
.
9
1
)
0
.
2
3
0
.
2
5
1
4
0
3
1
/
1
7
0
1
6
0
.
0
4
5
6
.
0
7
e
-
1
0
0
.
8
9
 
(
0
.
8
5
 
t
o
 
0
.
9
2
)
r
s
5
0
2
9
9
3
7
6
q
2
3
0
.
0
5
0
.
0
4
5
4
6
9
/
6
0
2
4
0
.
2
3
1
6
.
8
4
e
-
0
8
1
.
4
3
 
(
1
.
3
0
 
t
o
 
1
.
6
3
)
0
.
0
5
0
.
0
3
7
7
3
1
/
9
4
0
3
0
.
2
5
6
4
.
6
2
e
-
1
0
1
.
4
2
 
(
1
.
2
7
 
t
o
 
1
.
5
9
)
r
s
6
8
2
2
8
4
4
I
L
2
/
I
L
2
1
0
.
1
6
0
.
1
9
9
8
1
0
/
1
0
0
3
1
0
.
5
0
5
5
.
7
0
e
-
1
0
0
.
8
5
 
(
0
.
8
0
 
t
o
 
0
.
8
9
)
0
.
1
6
0
.
1
8
1
2
9
5
3
/
1
3
3
7
0
0
.
0
8
5
5
.
8
9
e
-
0
8
0
.
8
8
 
(
0
.
8
4
 
t
o
 
0
.
9
2
)
r
s
6
9
2
0
2
2
0
6
q
2
3
0
.
2
3
0
.
2
0
1
1
4
2
0
/
1
1
0
0
8
0
.
3
8
3
5
.
9
0
e
-
1
6
1
.
2
1
 
(
1
.
1
5
 
t
o
 
1
.
2
6
)
0
.
2
3
0
.
2
0
1
4
5
6
6
/
1
4
4
1
5
0
.
3
1
6
1
.
0
8
e
-
1
5
1
.
1
8
 
(
1
.
1
4
 
t
o
 
1
.
2
3
)
r
s
7
5
7
4
8
6
5
S
T
A
T
4
0
.
2
5
0
.
2
2
1
1
3
3
1
/
1
2
8
1
4
0
.
4
6
2
2
.
7
6
e
-
1
6
1
.
2
0
 
(
1
.
1
5
 
t
o
 
1
.
2
5
)
0
.
2
5
0
.
2
2
1
4
3
9
4
/
1
6
1
3
1
0
.
3
0
7
2
.
9
9
e
-
1
5
1
.
1
8
 
(
1
.
1
4
 
t
o
 
1
.
2
3
)
r
s
1
0
7
6
0
1
3
0
T
R
A
F
1
/
C
5
0
.
4
7
0
.
4
2
7
3
8
1
/
9
9
2
7
5
.
8
6
e
-
0
6
8
.
8
4
e
-
1
2
1
.
1
6
 
(
1
.
1
2
 
t
o
 
1
.
2
2
)
0
.
4
6
0
.
4
3
1
0
5
3
6
/
1
3
2
6
9
9
.
6
2
e
-
0
6
6
.
0
3
e
-
1
2
1
.
1
5
 
(
1
.
1
0
 
t
o
 
1
.
1
9
)
r
s
1
3
2
0
7
0
3
3
6
q
2
3
0
.
2
4
0
.
2
7
1
0
3
0
1
/
1
0
4
3
6
0
.
0
9
2
1
.
4
0
e
-
0
7
0
.
8
9
 
(
0
.
8
5
 
t
o
 
0
.
9
3
)
0
.
2
4
0
.
2
7
1
3
2
8
5
/
1
3
8
1
8
0
.
0
3
9
2
.
5
2
e
-
0
7
0
.
9
0
 
(
0
.
8
6
 
t
o
 
0
.
9
4
)
χ
²
 
p
,
 
χ
²
 
p
 
v
a
l
u
e
;
 
H
e
t
 
p
,
 
h
e
t
e
r
o
g
e
n
e
i
t
y
 
χ
²
 
p
 
v
a
l
u
e
;
 
S
N
P
,
 
s
i
n
g
l
e
-
n
u
c
l
e
o
t
i
d
e
 
p
o
l
y
m
o
r
p
h
i
s
m
.
24_annrheumdis121020.indd   1551 24_annrheumdis121020.indd   1551 7/5/2010   3:32:26 PM 7/5/2010   3:32:26 PMExtended report
Ann Rheum Dis 2010;69:1548–1553. doi:10.1136/ard.2009.121020 1552
TRAF1/C5 locus showed that the mean OR was 1.15 (95% CI 
1.05 to 1.26) and 1.16 (95% CI 1.07 to 1.26) for rs2900180 and 
rs10760130, respectively. Between-study heterogeneity at the 
TRAF1/C5 locus has previously been reported.24 Underlying 
differences in effects may be reﬂ  ective of population stratiﬁ  ca-
tion. We tried to avoid a pooling strategy in the meta-analysis 
where possible; however, the Swedish and Danish patient 
samples were pooled owing to a lack of healthy controls for 
these patients.
A weakness in this study was that ancestry informative mark-
ers were not available to more formally assess genetic differ-
ences due to differences in geographical location.
There is emerging evidence that different genetic effects exist 
in serologically deﬁ  ned patient groups.25 26 We performed meta-
analyses of genetic markers in serologically deﬁ  ned patients 
within GRACE, in which we analysed anti-citrullinated protein 
antibody (ACPA)-positive patients separately (online supple-
mentary table 4). The number of observations in the subanaly-
ses was modest; however, eight SNP markers were associated 
with ACPA-positive RA: rs1160542 (AFF3), rs1678542 (KIF5A), 
rs2476601 (PTPN22), rs2900180 and rs10760130 (TRAF1/C5) 
rs4810485 (CD40), rs5029937 (6q23) and rs7574865 (STAT4). 
For SNPs that were associated with RA in the ACPA-positive 
subgroup, the effect was predominantly greater (table 2 and 
online supplementary table 4). The current meta-analysis 
of GRACE data and previously published studies included 
data from cohorts of anti-cyclic citrullinated peptide-positive 
patients with RA,13 and cohorts in which no formal subdivision 
results were comparable to those previously reported.3–5 14 
Where SNPs failed to replicate we had between 10% and 93% 
power to detect an effect size of the same magnitude previ-
ously reported.
The well-established RA susceptibility SNP within PTPN22 
(rs2476601) appeared not to associate with RA in patients from 
Crete, Greece. This might be owing to a lack of power resulting 
from small sample size. Given the minor allele frequency of the 
PTPN22 variant in Crete control samples (3%), ~5000 patient 
and control samples would be required to detect even a large 
effect at this locus—that is, a 50% increase in risk with 80% 
power at p=0.05. The minor allele for rs2476601 was observed 
at low frequency in patients from Crete (4%), similar to that 
seen in the Turkish population (3%)—where no association 
with RA has been detected.23 There remains no supportive 
evidence for a signiﬁ  cant effect at the PTPN22 locus in South-
Eastern European patients with RA.
In the meta-analysis incorporating previously published 
results, all 18 SNPs signiﬁ  cantly associated with RA suscep-
tibility. The association of nine SNPs (rs231775, rs763361, 
rs1160542, rs1678542, rs2104286, rs2476601, rs2900180, 
rs3087243 and rs5029937) increased in signiﬁ  cance by  inclusion 
of GRACE cohort data (table 3). Signiﬁ  cant  between-study 
heterogeneity was observed for SNPs at PTPN22 (ﬁ  gure 1). 
Applying a random effects model to the meta-data showed 
that the mean OR for rs2476601 was 1.64 (95% CI 1.52 to 
1.77). Between-study variation in effect size was also seen for 
the TRAF1/C5 SNPs. Applying random effects models at the 
Figure 1  Meta-analysis of previously published data, together with data generated in this study (labelled: UK_rep2 (UK), Greece, France, Germany 
and EIRA for Scandinavian cohorts) for the single-nucleotide polymorphism maker rs2476601 (PTPN22). Odds ratio (OR) point estimate and 95% CI 
(horizontal line) for each cohort are shown. The diamond represents the meta-analysis point estimate and CI. The scale of the effect size is given on 
the x-axis. EIRA, Epidemiological Investigation of Rheumatoid Arthritis; WTCCC, Wellcome Trust Case Control Consortium.
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Genet 2007;39:1431–3.
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2005;6:459–61.
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risk locus for autoimmune diseases. Am J Hum Genet 2007;81:1284–8.
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1987 revised criteria for the classiﬁ  cation of rheumatoid arthritis. Arthritis Rheum 
1988;31:315–24.
22.  MacGregor AJ, Bamber S, Silman AJ. A comparison of the performance of different 
methods of disease classiﬁ  cation for rheumatoid arthritis. Results of an analysis from 
a nationwide twin study. J Rheumatol 1994;21:1420–6.
23.  Sahin N, Gunduz F, Inanc N, et al. No association of PTPN22 gene 
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TRAF1-C5 and 6q23 loci: a meta-analysis. Ann Rheum Dis 2010;69:561-6.
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26.  van der Helm-van Mil AH, Huizinga TW, de Vries RR, et al. Emerging patterns of 
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had been performed.16 This meta-analysis is therefore hetero-
geneous with respect to seropositivity and future studies tak-
ing account of subphenotypes may disclose different genetic 
associations.
In this large pan-European collaboration we have established 
a replication cohort of up to 7000 patients and controls from six 
countries. In an initial experiment using this material we provide 
additional evidence to support 18 loci as susceptibility markers 
for RA in people of European ancestry.
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